Claudin 18.2 Targeted Therapy Market Size, Share Report 2026

What Market Size Is Projected For The Claudin 18.2 Targeted Therapy Market By 2030?
The claudin 18.2 targeted therapy market size has grown exponentially in recent years. It will grow from $1.6 billion in 2025 to $1.98 billion in 2026 at a compound annual growth rate (CAGR) of 23.7%. The growth in the historic period can be attributed to increasing prevalence of gastric and gastrointestinal cancers, advancements in antibody engineering technologies, expansion of oncology-focused clinical trials, rising investments in targeted cancer therapies, improved understanding of claudin protein biology.

The claudin 18.2 targeted therapy market size is expected to see exponential growth in the next few years. It will grow to $4.61 billion in 2030 at a compound annual growth rate (CAGR) of 23.5%. The growth in the forecast period can be attributed to increasing regulatory approvals for targeted oncology drugs, rising demand for personalized cancer treatment, expansion of combination therapy approaches, growing oncology pipeline investments, increasing adoption of precision diagnostics. Major trends in the forecast period include increasing focus on biomarker-driven oncology therapies, rising development of claudin 18.2 monoclonal antibodies, growing expansion of indication-specific targeted treatments, enhanced integration of companion diagnostics, increasing strategic collaborations in precision oncology.

Claim Your Free Report Sample Today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=28169&type=smp

Which Primary Market Drivers Are Fueling Momentum In The Claudin 18.2 Targeted Therapy Market?
The rising incidence of gastrointestinal cancers is expected to propel the growth of the claudin 18.2 targeted therapy market going forward. Gastrointestinal (GI) cancers refer to malignant tumors that develop in any part of the digestive tract, from the esophagus to the rectum. The rise in gastrointestinal cancers is largely due to unhealthy diets rich in processed foods and low in fiber, promoting gut inflammation and increasing cancer risk. Claudin 18.2 targeted therapy helps treat gastrointestinal cancers by selectively targeting the Claudin 18.2 protein, overexpressed on cancer cells, enabling drugs or antibodies to kill cancer cells while sparing healthy tissue and improving treatment effectiveness. For instance, in June 2025, according to the Centers for Disease Control and Prevention (CDC), a US-based public health agency, 147,931 new colorectal cancer cases were reported in 2022, and 53,779 deaths from colorectal cancer were recorded in 2023. Therefore, the rising incidence of gastrointestinal cancers is driving the growth of the Claudin 18.2 targeted therapy market.

What Major Market Segments Contribute To Shaping The Overall Framework Of The Claudin 18.2 Targeted Therapy Market?
The claudin 18.2 targeted therapy market covered in this report is segmented –

1) By Therapy Type: Monoclonal Antibodies, Bispecific Antibodies, Antibody-Drug Conjugates, Other Therapy Types
2) By Indication: Gastric Cancer, Pancreatic Cancer, Esophageal Cancer, Other Indications
3) By Route Of Administration: Intravenous, Oral, Other Route Of Administrations
4) By End-User: Hospitals, Oncology Centers, Research Institutes, Other End-Users

Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Bispecific Antibodies: Igg-Like Bispecific Antibodies, Non-Igg-Like Bispecific Antibodies
3) By Antibody-Drug Conjugates: Microtubule Inhibitor-Based Antibody-Drug Conjugates, Dna Damaging Agent-Based Antibody-Drug Conjugates, Topoisomerase Inhibitor-Based Antibody-Drug Conjugates
4) By Other Therapy Types: Car-T Cell Therapy, Vaccines, Small Molecule Inhibitors

What Major Trends Are Set To Shape The Claudin 18.2 Targeted Therapy Market Outlook Through The Forecast Period?
Major companies operating in the claudin 18.2 targeted therapy market are focusing on developing innovative solutions, such as monoclonal antibodies, to specifically target claudin 18.2-expressing cancer cells and enhance treatment outcomes. A monoclonal antibody is a laboratory-engineered protein designed to bind precisely to a single target, such as a protein on the surface of cancer cells, aiding the immune system in recognizing and attacking these cells. For instance, in March 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, obtained approval from Japan's Ministry of Health, Labour and Welfare for VYLOY (zolbetuximab) for the treatment of patients with CLDN18.2-positive cancer. This targeted therapy for advanced gastric and gastroesophageal junction cancer selectively binds to the CLDN18.2 protein on tumor cells, activating the immune system to destroy cancer cells. Clinical trials showed it significantly improves progression-free and overall survival when combined with chemotherapy compared to chemotherapy alone. This innovative therapy provides a new, effective option for patients with HER2-negative, CLDN18.2-positive tumors, fulfilling an unmet need in aggressive gastric cancer.

Who Are The Established And Emerging Players Expanding Their Footprint In The Claudin 18.2 Targeted Therapy Market?
Major companies operating in the claudin 18.2 targeted therapy market are Bristol Myers Squibb Company, Amgen Inc., Astellas Pharma Inc., Jiangsu Hengrui Medicine Co. Ltd., Shanghai Henlius Biotech Inc., Legend Biotech Corporation, Zai Lab Limited, Harbour Biomed Ltd., CARsgen Therapeutics Holdings Limited, Genor Biopharma Co. Ltd., Phanes Therapeutics Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Triumvira Immunologics Inc., SOTIO Biotech a.s., Leap Therapeutics, Allogene Therapeutics, AskGene Pharma Inc., Elpiscience Biopharmaceutical Co. Ltd., I-Mab Biopharma Co. Ltd., Antegene Biopharma Co. Ltd.

Get Your In-Depth Claudin 18.2 Targeted Therapy Market Report Now:
https://www.thebusinessresearchcompany.com/report/claudin-182-targeted-therapy-global-market-report

Which Regional Clusters Are Forecasted To Outperform Others In The Claudin 18.2 Targeted Therapy Market?
Asia-Pacific was the largest region in the claudin 18.2 targeted therapy market in 2025. The regions covered in the claudin 18.2 targeted therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:

The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company